Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC (Original PDF from Publisher)

Fast Facts EGFR Exon 20 Insertion Mutations in NSCLC

Although lung cancer remains a leading cause of mortality worldwide, the advancement of customized, precision medicine has significantly improved clinical outcomes and therapeutic management, especially for patients with advanced non-small-cell lung cancer (NSCLC). The third most frequent mutation discovered in patients with advanced stage non-small cell lung cancer is an EGFR mutation. Most patients should receive first-line treatment with a conventional EGFR tyrosine kinase inhibitor (TKI); however, patients with EGFR exon 20 insertion mutations (ex20ins) should not. Rather, there is hope for better results in this patient group due to the recent approval of a bispecific antibody (amivantamab) that targets both EGFR and mesenchymalepithelial transition factor (MET) and a TKI (mobocertinib) that is specific to EGFR ex20ins. Additionally, trials for novel medicines with increased activity against ex20ins mutations are still underway, and new therapeutic strategies are constantly being developed.